Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-cash Items: 2021-2024

Historic Non-cash Items for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $7.7 million.

  • Kiniksa Pharmaceuticals International's Non-cash Items fell 12.67% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 12.67%. This contributed to the annual value of $7.7 million for FY2024, which is 85.96% down from last year.
  • Kiniksa Pharmaceuticals International's Non-cash Items amounted to $7.7 million in FY2024, which was down 85.96% from $54.7 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Non-cash Items' 5-year high stood at $54.7 million during FY2023, with a 5-year trough of $4.7 million in FY2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Non-cash Items had a median value of $32.6 million in 2022 and averaged $31.7 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 589.47% in 2022, then slumped by 85.96% in 2024.
  • Kiniksa Pharmaceuticals International's Non-cash Items (Yearly) stood at $4.7 million in 2021, then soared by 589.47% to $32.6 million in 2022, then surged by 67.47% to $54.7 million in 2023, then slumped by 85.96% to $7.7 million in 2024.